Industry Research Reports

Home > Reports > Medical Care > Dendritic Cell Cancer Vaccines - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Dendritic Cell Cancer Vaccines - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Industry: Medical Care

Published: 2024-01-24

Pages: 123 Pages

Report ld: 2334614

Description
Table of Contents
Table of Figures
PDF Download

Description
Table of Contents
Table of Figures
PDF Download

Description

Dendritic cells (DCs) refer to rare kind of leukocytes. They have prompted their recent application to therapeutic cancer vaccinations as they are uniquely effective in their ability to present antigens to T cells. Isolated DCs loaded with tumor antigen ex vivo and administered as a cellular vaccine are found to induce protective and therapeutic anti-tumor immunity in experimental animals.

The global market for Dendritic Cell Cancer Vaccines was estimated to be worth US$ 601.3 million in 2023 and is forecast to a readjusted size of US$ 1436.3 million by 2030 with a CAGR of 13.1% during the forecast period 2024-2030

Dendritic Cell Cancer Vaccines Market Size

M= millions and B=billions

Among all the currently available immunotherapy strategies, dendritic cell vaccines are the most potent antigen-presenting cells for the effective proliferation of T-cells. The specificity of the treatment has boosted its range of applications and is also witnessing global acceptance. As a result, several companies are collaborating to introduce a novel product. For instance, in March 2022, BioNTech signed into a collaboration with Medigene by which Medigene received USD 29 million as an upfront research fund for the co-development of immunotherapies focusing on multiple types of carcinoma. Further, BioNTech will utilize Medigene’s discovery platform and successfully acquire a preclinical asset. Immunotherapy has great potential for treating minimal residual disease (MRD) by the use of dendritic cells and many studies have yielded promising results with no signs of recurrence of tumor growth. For instance, in May 2022, researchers of the AML-VACCiN consortium, clinically developed a dendritic cell vaccine- DCP-001, so as to vaccinate patients with acute myeloid leukemia to eradicate MRD and to effectively reduce the risk of a relapse. The vaccine candidate is designated as an orphan medicinal product in the EU after reliable results from trial phases I & II.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Dendritic Cell Cancer Vaccines, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Dendritic Cell Cancer Vaccines by region & country, by Type, and by Application.

The Dendritic Cell Cancer Vaccines market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Dendritic Cell Cancer Vaccines.

Market Segmentation

Report Metric
Details
Report Title
Dendritic Cell Cancer Vaccines - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Forecasted Market Size in 2030
US$ 1436.3 million
CAGR(2024-2030)
13.1%
Market Size Available for Years
2019-2030
Global Dendritic Cell Cancer Vaccines Companies Covered
3M Company, Activarti, Argos Therapeutics, Batavia Bioservices, Bellicum Pharmaceuticals, Creagene, DanDrit Biotech, DCPrime, Sanpower Corporation, Elios Therapeutics, ImmunoCellular Therapeutics, Immunicum, Kiromic, Medigene, Merck, Northwest Biotherapeutics, Glaxo Smith Kline, Tellaorporation, Vaxil BioTherapeutics
Global Dendritic Cell Cancer Vaccines Market, by Region
North America (U.S., Canada, Mexico)

Europe (Germany, France, UK, Italy, etc.)

Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)

South America (Brazil, etc.)

Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Dendritic Cell Cancer Vaccines Market, Segment by Type
CreaVax

Sipuleucel-T (Provenge)

Others
Global Dendritic Cell Cancer Vaccines Market, Segment by Application
Pediatrics

Adults
Forecast Units
USD million in value
Report Coverage
Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Dendritic Cell Cancer Vaccines manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Dendritic Cell Cancer Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Dendritic Cell Cancer Vaccines in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Table of Contents

 1 Market Overview
    1.1 Dendritic Cell Cancer Vaccines Product Introduction
    1.2 Global Dendritic Cell Cancer Vaccines Market Size Forecast
    1.3 Dendritic Cell Cancer Vaccines Market Trends & Drivers
        1.3.1 Dendritic Cell Cancer Vaccines Industry Trends
        1.3.2 Dendritic Cell Cancer Vaccines Market Drivers & Opportunity
        1.3.3 Dendritic Cell Cancer Vaccines Market Challenges
        1.3.4 Dendritic Cell Cancer Vaccines Market Restraints
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered

 2 Competitive Analysis by Company
    2.1 Global Dendritic Cell Cancer Vaccines Players Revenue Ranking (2023)
    2.2 Global Dendritic Cell Cancer Vaccines Revenue by Company (2019-2024)
    2.3 Key Companies Dendritic Cell Cancer Vaccines Manufacturing Base Distribution and Headquarters
    2.4 Key Companies Dendritic Cell Cancer Vaccines Product Offered
    2.5 Key Companies Time to Begin Mass Production of Dendritic Cell Cancer Vaccines
    2.6 Dendritic Cell Cancer Vaccines Market Competitive Analysis
        2.6.1 Dendritic Cell Cancer Vaccines Market Concentration Rate (2019-2024)
        2.6.2 Global 5 and 10 Largest Companies by Dendritic Cell Cancer Vaccines Revenue in 2023
        2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Dendritic Cell Cancer Vaccines as of 2023)
    2.7 Mergers & Acquisitions, Expansion

 3 Segmentation by Type
    3.1 Introduction by Type
        3.1.1 CreaVax
        3.1.2 Sipuleucel-T (Provenge)
        3.1.3 Others
    3.2 Global Dendritic Cell Cancer Vaccines Sales Value by Type
        3.2.1 Global Dendritic Cell Cancer Vaccines Sales Value by Type (2019 VS 2023 VS 2030)
        3.2.2 Global Dendritic Cell Cancer Vaccines Sales Value, by Type (2019-2030)
        3.2.3 Global Dendritic Cell Cancer Vaccines Sales Value, by Type (%) (2019-2030)

 4 Segmentation by Application
    4.1 Introduction by Application
        4.1.1 Pediatrics
        4.1.2 Adults
    4.2 Global Dendritic Cell Cancer Vaccines Sales Value by Application
        4.2.1 Global Dendritic Cell Cancer Vaccines Sales Value by Application (2019 VS 2023 VS 2030)
        4.2.2 Global Dendritic Cell Cancer Vaccines Sales Value, by Application (2019-2030)
        4.2.3 Global Dendritic Cell Cancer Vaccines Sales Value, by Application (%) (2019-2030)

 5 Segmentation by Region
    5.1 Global Dendritic Cell Cancer Vaccines Sales Value by Region
        5.1.1 Global Dendritic Cell Cancer Vaccines Sales Value by Region: 2019 VS 2023 VS 2030
        5.1.2 Global Dendritic Cell Cancer Vaccines Sales Value by Region (2019-2024)
        5.1.3 Global Dendritic Cell Cancer Vaccines Sales Value by Region (2025-2030)
        5.1.4 Global Dendritic Cell Cancer Vaccines Sales Value by Region (%), (2019-2030)
    5.2 North America
        5.2.1 North America Dendritic Cell Cancer Vaccines Sales Value, 2019-2030
        5.2.2 North America Dendritic Cell Cancer Vaccines Sales Value by Country (%), 2023 VS 2030
    5.3 Europe
        5.3.1 Europe Dendritic Cell Cancer Vaccines Sales Value, 2019-2030
        5.3.2 Europe Dendritic Cell Cancer Vaccines Sales Value by Country (%), 2023 VS 2030
    5.4 Asia Pacific
        5.4.1 Asia Pacific Dendritic Cell Cancer Vaccines Sales Value, 2019-2030
        5.4.2 Asia Pacific Dendritic Cell Cancer Vaccines Sales Value by Country (%), 2023 VS 2030
    5.5 South America
        5.5.1 South America Dendritic Cell Cancer Vaccines Sales Value, 2019-2030
        5.5.2 South America Dendritic Cell Cancer Vaccines Sales Value by Country (%), 2023 VS 2030
    5.6 Middle East & Africa
        5.6.1 Middle East & Africa Dendritic Cell Cancer Vaccines Sales Value, 2019-2030
        5.6.2 Middle East & Africa Dendritic Cell Cancer Vaccines Sales Value by Country (%), 2023 VS 2030

 6 Segmentation by Key Countries/Regions
    6.1 Key Countries/Regions Dendritic Cell Cancer Vaccines Sales Value Growth Trends, 2019 VS 2023 VS 2030
    6.2 Key Countries/Regions Dendritic Cell Cancer Vaccines Sales Value
    6.3 United States
        6.3.1 United States Dendritic Cell Cancer Vaccines Sales Value, 2019-2030
        6.3.2 United States Dendritic Cell Cancer Vaccines Sales Value by Type (%), 2023 VS 2030
        6.3.3 United States Dendritic Cell Cancer Vaccines Sales Value by Application, 2023 VS 2030
    6.4 Europe
        6.4.1 Europe Dendritic Cell Cancer Vaccines Sales Value, 2019-2030
        6.4.2 Europe Dendritic Cell Cancer Vaccines Sales Value by Type (%), 2023 VS 2030
        6.4.3 Europe Dendritic Cell Cancer Vaccines Sales Value by Application, 2023 VS 2030
    6.5 China
        6.5.1 China Dendritic Cell Cancer Vaccines Sales Value, 2019-2030
        6.5.2 China Dendritic Cell Cancer Vaccines Sales Value by Type (%), 2023 VS 2030
        6.5.3 China Dendritic Cell Cancer Vaccines Sales Value by Application, 2023 VS 2030
    6.6 Japan
        6.6.1 Japan Dendritic Cell Cancer Vaccines Sales Value, 2019-2030
        6.6.2 Japan Dendritic Cell Cancer Vaccines Sales Value by Type (%), 2023 VS 2030
        6.6.3 Japan Dendritic Cell Cancer Vaccines Sales Value by Application, 2023 VS 2030
    6.7 South Korea
        6.7.1 South Korea Dendritic Cell Cancer Vaccines Sales Value, 2019-2030
        6.7.2 South Korea Dendritic Cell Cancer Vaccines Sales Value by Type (%), 2023 VS 2030
        6.7.3 South Korea Dendritic Cell Cancer Vaccines Sales Value by Application, 2023 VS 2030
    6.8 Southeast Asia
        6.8.1 Southeast Asia Dendritic Cell Cancer Vaccines Sales Value, 2019-2030
        6.8.2 Southeast Asia Dendritic Cell Cancer Vaccines Sales Value by Type (%), 2023 VS 2030
        6.8.3 Southeast Asia Dendritic Cell Cancer Vaccines Sales Value by Application, 2023 VS 2030
    6.9 India
        6.9.1 India Dendritic Cell Cancer Vaccines Sales Value, 2019-2030
        6.9.2 India Dendritic Cell Cancer Vaccines Sales Value by Type (%), 2023 VS 2030
        6.9.3 India Dendritic Cell Cancer Vaccines Sales Value by Application, 2023 VS 2030

 7 Company Profiles
    7.1 3M Company
        7.1.1 3M Company Profile
        7.1.2 3M Company Main Business
        7.1.3 3M Company Dendritic Cell Cancer Vaccines Products, Services and Solutions
        7.1.4 3M Company Dendritic Cell Cancer Vaccines Revenue (US$ Million) & (2019-2024)
        7.1.5 3M Company Recent Developments
    7.2 Activarti
        7.2.1 Activarti Profile
        7.2.2 Activarti Main Business
        7.2.3 Activarti Dendritic Cell Cancer Vaccines Products, Services and Solutions
        7.2.4 Activarti Dendritic Cell Cancer Vaccines Revenue (US$ Million) & (2019-2024)
        7.2.5 Activarti Recent Developments
    7.3 Argos Therapeutics
        7.3.1 Argos Therapeutics Profile
        7.3.2 Argos Therapeutics Main Business
        7.3.3 Argos Therapeutics Dendritic Cell Cancer Vaccines Products, Services and Solutions
        7.3.4 Argos Therapeutics Dendritic Cell Cancer Vaccines Revenue (US$ Million) & (2019-2024)
        7.3.5 Batavia Bioservices Recent Developments
    7.4 Batavia Bioservices
        7.4.1 Batavia Bioservices Profile
        7.4.2 Batavia Bioservices Main Business
        7.4.3 Batavia Bioservices Dendritic Cell Cancer Vaccines Products, Services and Solutions
        7.4.4 Batavia Bioservices Dendritic Cell Cancer Vaccines Revenue (US$ Million) & (2019-2024)
        7.4.5 Batavia Bioservices Recent Developments
    7.5 Bellicum Pharmaceuticals
        7.5.1 Bellicum Pharmaceuticals Profile
        7.5.2 Bellicum Pharmaceuticals Main Business
        7.5.3 Bellicum Pharmaceuticals Dendritic Cell Cancer Vaccines Products, Services and Solutions
        7.5.4 Bellicum Pharmaceuticals Dendritic Cell Cancer Vaccines Revenue (US$ Million) & (2019-2024)
        7.5.5 Bellicum Pharmaceuticals Recent Developments
    7.6 Creagene
        7.6.1 Creagene Profile
        7.6.2 Creagene Main Business
        7.6.3 Creagene Dendritic Cell Cancer Vaccines Products, Services and Solutions
        7.6.4 Creagene Dendritic Cell Cancer Vaccines Revenue (US$ Million) & (2019-2024)
        7.6.5 Creagene Recent Developments
    7.7 DanDrit Biotech
        7.7.1 DanDrit Biotech Profile
        7.7.2 DanDrit Biotech Main Business
        7.7.3 DanDrit Biotech Dendritic Cell Cancer Vaccines Products, Services and Solutions
        7.7.4 DanDrit Biotech Dendritic Cell Cancer Vaccines Revenue (US$ Million) & (2019-2024)
        7.7.5 DanDrit Biotech Recent Developments
    7.8 DCPrime
        7.8.1 DCPrime Profile
        7.8.2 DCPrime Main Business
        7.8.3 DCPrime Dendritic Cell Cancer Vaccines Products, Services and Solutions
        7.8.4 DCPrime Dendritic Cell Cancer Vaccines Revenue (US$ Million) & (2019-2024)
        7.8.5 DCPrime Recent Developments
    7.9 Sanpower Corporation
        7.9.1 Sanpower Corporation Profile
        7.9.2 Sanpower Corporation Main Business
        7.9.3 Sanpower Corporation Dendritic Cell Cancer Vaccines Products, Services and Solutions
        7.9.4 Sanpower Corporation Dendritic Cell Cancer Vaccines Revenue (US$ Million) & (2019-2024)
        7.9.5 Sanpower Corporation Recent Developments
    7.10 Elios Therapeutics
        7.10.1 Elios Therapeutics Profile
        7.10.2 Elios Therapeutics Main Business
        7.10.3 Elios Therapeutics Dendritic Cell Cancer Vaccines Products, Services and Solutions
        7.10.4 Elios Therapeutics Dendritic Cell Cancer Vaccines Revenue (US$ Million) & (2019-2024)
        7.10.5 Elios Therapeutics Recent Developments
    7.11 ImmunoCellular Therapeutics
        7.11.1 ImmunoCellular Therapeutics Profile
        7.11.2 ImmunoCellular Therapeutics Main Business
        7.11.3 ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccines Products, Services and Solutions
        7.11.4 ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccines Revenue (US$ Million) & (2019-2024)
        7.11.5 ImmunoCellular Therapeutics Recent Developments
    7.12 Immunicum
        7.12.1 Immunicum Profile
        7.12.2 Immunicum Main Business
        7.12.3 Immunicum Dendritic Cell Cancer Vaccines Products, Services and Solutions
        7.12.4 Immunicum Dendritic Cell Cancer Vaccines Revenue (US$ Million) & (2019-2024)
        7.12.5 Immunicum Recent Developments
    7.13 Kiromic
        7.13.1 Kiromic Profile
        7.13.2 Kiromic Main Business
        7.13.3 Kiromic Dendritic Cell Cancer Vaccines Products, Services and Solutions
        7.13.4 Kiromic Dendritic Cell Cancer Vaccines Revenue (US$ Million) & (2019-2024)
        7.13.5 Kiromic Recent Developments
    7.14 Medigene
        7.14.1 Medigene Profile
        7.14.2 Medigene Main Business
        7.14.3 Medigene Dendritic Cell Cancer Vaccines Products, Services and Solutions
        7.14.4 Medigene Dendritic Cell Cancer Vaccines Revenue (US$ Million) & (2019-2024)
        7.14.5 Medigene Recent Developments
    7.15 Merck
        7.15.1 Merck Profile
        7.15.2 Merck Main Business
        7.15.3 Merck Dendritic Cell Cancer Vaccines Products, Services and Solutions
        7.15.4 Merck Dendritic Cell Cancer Vaccines Revenue (US$ Million) & (2019-2024)
        7.15.5 Merck Recent Developments
    7.16 Northwest Biotherapeutics
        7.16.1 Northwest Biotherapeutics Profile
        7.16.2 Northwest Biotherapeutics Main Business
        7.16.3 Northwest Biotherapeutics Dendritic Cell Cancer Vaccines Products, Services and Solutions
        7.16.4 Northwest Biotherapeutics Dendritic Cell Cancer Vaccines Revenue (US$ Million) & (2019-2024)
        7.16.5 Northwest Biotherapeutics Recent Developments
    7.17 Glaxo Smith Kline
        7.17.1 Glaxo Smith Kline Profile
        7.17.2 Glaxo Smith Kline Main Business
        7.17.3 Glaxo Smith Kline Dendritic Cell Cancer Vaccines Products, Services and Solutions
        7.17.4 Glaxo Smith Kline Dendritic Cell Cancer Vaccines Revenue (US$ Million) & (2019-2024)
        7.17.5 Glaxo Smith Kline Recent Developments
    7.18 Tellaorporation
        7.18.1 Tellaorporation Profile
        7.18.2 Tellaorporation Main Business
        7.18.3 Tellaorporation Dendritic Cell Cancer Vaccines Products, Services and Solutions
        7.18.4 Tellaorporation Dendritic Cell Cancer Vaccines Revenue (US$ Million) & (2019-2024)
        7.18.5 Tellaorporation Recent Developments
    7.19 Vaxil BioTherapeutics
        7.19.1 Vaxil BioTherapeutics Profile
        7.19.2 Vaxil BioTherapeutics Main Business
        7.19.3 Vaxil BioTherapeutics Dendritic Cell Cancer Vaccines Products, Services and Solutions
        7.19.4 Vaxil BioTherapeutics Dendritic Cell Cancer Vaccines Revenue (US$ Million) & (2019-2024)
        7.19.5 Vaxil BioTherapeutics Recent Developments

 8 Industry Chain Analysis
    8.1 Dendritic Cell Cancer Vaccines Industrial Chain
    8.2 Dendritic Cell Cancer Vaccines Upstream Analysis
        8.2.1 Key Raw Materials
        8.2.2 Raw Materials Key Suppliers
        8.2.3 Manufacturing Cost Structure
    8.3 Midstream Analysis
    8.4 Downstream Analysis (Customers Analysis)
    8.5 Sales Model and Sales Channels
        8.5.1 Dendritic Cell Cancer Vaccines Sales Model
        8.5.2 Sales Channel
        8.5.3 Dendritic Cell Cancer Vaccines Distributors

 9 Research Findings and Conclusion

 10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
        10.1.2 Data Source
    10.2 Author Details
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Dendritic Cell Cancer Vaccines Market Trends
    Table 2. Dendritic Cell Cancer Vaccines Market Drivers & Opportunity
    Table 3. Dendritic Cell Cancer Vaccines Market Challenges
    Table 4. Dendritic Cell Cancer Vaccines Market Restraints
    Table 5. Global Dendritic Cell Cancer Vaccines Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Dendritic Cell Cancer Vaccines Revenue Market Share by Company (2019-2024)
    Table 7. Key Companies Dendritic Cell Cancer Vaccines Manufacturing Base Distribution and Headquarters
    Table 8. Key Companies Dendritic Cell Cancer Vaccines Product Type
    Table 9. Key Companies Time to Begin Mass Production of Dendritic Cell Cancer Vaccines
    Table 10. Global Dendritic Cell Cancer Vaccines Companies Market Concentration Ratio (CR5 and HHI)
    Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Dendritic Cell Cancer Vaccines as of 2023)
    Table 12. Mergers & Acquisitions, Expansion Plans
    Table 13. Global Dendritic Cell Cancer Vaccines Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 14. Global Dendritic Cell Cancer Vaccines Sales Value by Type (2019-2024) & (US$ Million)
    Table 15. Global Dendritic Cell Cancer Vaccines Sales Value by Type (2025-2030) & (US$ Million)
    Table 16. Global Dendritic Cell Cancer Vaccines Sales Market Share in Value by Type (2019-2024) & (%)
    Table 17. Global Dendritic Cell Cancer Vaccines Sales Market Share in Value by Type (2025-2030) & (%)
    Table 18. Global Dendritic Cell Cancer Vaccines Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 19. Global Dendritic Cell Cancer Vaccines Sales Value by Application (2019-2024) & (US$ Million)
    Table 20. Global Dendritic Cell Cancer Vaccines Sales Value by Application (2025-2030) & (US$ Million)
    Table 21. Global Dendritic Cell Cancer Vaccines Sales Market Share in Value by Application (2019-2024) & (%)
    Table 22. Global Dendritic Cell Cancer Vaccines Sales Market Share in Value by Application (2025-2030) & (%)
    Table 23. Global Dendritic Cell Cancer Vaccines Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 24. Global Dendritic Cell Cancer Vaccines Sales Value by Region (2019-2024) & (US$ Million)
    Table 25. Global Dendritic Cell Cancer Vaccines Sales Value by Region (2025-2030) & (US$ Million)
    Table 26. Global Dendritic Cell Cancer Vaccines Sales Value by Region (2019-2024) & (%)
    Table 27. Global Dendritic Cell Cancer Vaccines Sales Value by Region (2025-2030) & (%)
    Table 28. Key Countries/Regions Dendritic Cell Cancer Vaccines Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 29. Key Countries/Regions Dendritic Cell Cancer Vaccines Sales Value, (2019-2024) & (US$ Million)
    Table 30. Key Countries/Regions Dendritic Cell Cancer Vaccines Sales Value, (2025-2030) & (US$ Million)
    Table 31. 3M Company Basic Information List
    Table 32. 3M Company Description and Business Overview
    Table 33. 3M Company Dendritic Cell Cancer Vaccines Products, Services and Solutions
    Table 34. Revenue (US$ Million) in Dendritic Cell Cancer Vaccines Business of 3M Company (2019-2024)
    Table 35. 3M Company Recent Developments
    Table 36. Activarti Basic Information List
    Table 37. Activarti Description and Business Overview
    Table 38. Activarti Dendritic Cell Cancer Vaccines Products, Services and Solutions
    Table 39. Revenue (US$ Million) in Dendritic Cell Cancer Vaccines Business of Activarti (2019-2024)
    Table 40. Activarti Recent Developments
    Table 41. Argos Therapeutics Basic Information List
    Table 42. Argos Therapeutics Description and Business Overview
    Table 43. Argos Therapeutics Dendritic Cell Cancer Vaccines Products, Services and Solutions
    Table 44. Revenue (US$ Million) in Dendritic Cell Cancer Vaccines Business of Argos Therapeutics (2019-2024)
    Table 45. Argos Therapeutics Recent Developments
    Table 46. Batavia Bioservices Basic Information List
    Table 47. Batavia Bioservices Description and Business Overview
    Table 48. Batavia Bioservices Dendritic Cell Cancer Vaccines Products, Services and Solutions
    Table 49. Revenue (US$ Million) in Dendritic Cell Cancer Vaccines Business of Batavia Bioservices (2019-2024)
    Table 50. Batavia Bioservices Recent Developments
    Table 51. Bellicum Pharmaceuticals Basic Information List
    Table 52. Bellicum Pharmaceuticals Description and Business Overview
    Table 53. Bellicum Pharmaceuticals Dendritic Cell Cancer Vaccines Products, Services and Solutions
    Table 54. Revenue (US$ Million) in Dendritic Cell Cancer Vaccines Business of Bellicum Pharmaceuticals (2019-2024)
    Table 55. Bellicum Pharmaceuticals Recent Developments
    Table 56. Creagene Basic Information List
    Table 57. Creagene Description and Business Overview
    Table 58. Creagene Dendritic Cell Cancer Vaccines Products, Services and Solutions
    Table 59. Revenue (US$ Million) in Dendritic Cell Cancer Vaccines Business of Creagene (2019-2024)
    Table 60. Creagene Recent Developments
    Table 61. DanDrit Biotech Basic Information List
    Table 62. DanDrit Biotech Description and Business Overview
    Table 63. DanDrit Biotech Dendritic Cell Cancer Vaccines Products, Services and Solutions
    Table 64. Revenue (US$ Million) in Dendritic Cell Cancer Vaccines Business of DanDrit Biotech (2019-2024)
    Table 65. DanDrit Biotech Recent Developments
    Table 66. DCPrime Basic Information List
    Table 67. DCPrime Description and Business Overview
    Table 68. DCPrime Dendritic Cell Cancer Vaccines Products, Services and Solutions
    Table 69. Revenue (US$ Million) in Dendritic Cell Cancer Vaccines Business of DCPrime (2019-2024)
    Table 70. DCPrime Recent Developments
    Table 71. Sanpower Corporation Basic Information List
    Table 72. Sanpower Corporation Description and Business Overview
    Table 73. Sanpower Corporation Dendritic Cell Cancer Vaccines Products, Services and Solutions
    Table 74. Revenue (US$ Million) in Dendritic Cell Cancer Vaccines Business of Sanpower Corporation (2019-2024)
    Table 75. Sanpower Corporation Recent Developments
    Table 76. Elios Therapeutics Basic Information List
    Table 77. Elios Therapeutics Description and Business Overview
    Table 78. Elios Therapeutics Dendritic Cell Cancer Vaccines Products, Services and Solutions
    Table 79. Revenue (US$ Million) in Dendritic Cell Cancer Vaccines Business of Elios Therapeutics (2019-2024)
    Table 80. Elios Therapeutics Recent Developments
    Table 81. ImmunoCellular Therapeutics Basic Information List
    Table 82. ImmunoCellular Therapeutics Description and Business Overview
    Table 83. ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccines Products, Services and Solutions
    Table 84. Revenue (US$ Million) in Dendritic Cell Cancer Vaccines Business of ImmunoCellular Therapeutics (2019-2024)
    Table 85. ImmunoCellular Therapeutics Recent Developments
    Table 86. Immunicum Basic Information List
    Table 87. Immunicum Description and Business Overview
    Table 88. Immunicum Dendritic Cell Cancer Vaccines Products, Services and Solutions
    Table 89. Revenue (US$ Million) in Dendritic Cell Cancer Vaccines Business of Immunicum (2019-2024)
    Table 90. Immunicum Recent Developments
    Table 91. Kiromic Basic Information List
    Table 92. Kiromic Description and Business Overview
    Table 93. Kiromic Dendritic Cell Cancer Vaccines Products, Services and Solutions
    Table 94. Revenue (US$ Million) in Dendritic Cell Cancer Vaccines Business of Kiromic (2019-2024)
    Table 95. Kiromic Recent Developments
    Table 96. Medigene Basic Information List
    Table 97. Medigene Description and Business Overview
    Table 98. Medigene Dendritic Cell Cancer Vaccines Products, Services and Solutions
    Table 99. Revenue (US$ Million) in Dendritic Cell Cancer Vaccines Business of Medigene (2019-2024)
    Table 100. Medigene Recent Developments
    Table 101. Merck Basic Information List
    Table 102. Merck Description and Business Overview
    Table 103. Merck Dendritic Cell Cancer Vaccines Products, Services and Solutions
    Table 104. Revenue (US$ Million) in Dendritic Cell Cancer Vaccines Business of Merck (2019-2024)
    Table 105. Merck Recent Developments
    Table 106. Northwest Biotherapeutics Basic Information List
    Table 107. Northwest Biotherapeutics Description and Business Overview
    Table 108. Northwest Biotherapeutics Dendritic Cell Cancer Vaccines Products, Services and Solutions
    Table 109. Revenue (US$ Million) in Dendritic Cell Cancer Vaccines Business of Northwest Biotherapeutics (2019-2024)
    Table 110. Northwest Biotherapeutics Recent Developments
    Table 111. Glaxo Smith Kline Basic Information List
    Table 112. Glaxo Smith Kline Description and Business Overview
    Table 113. Glaxo Smith Kline Dendritic Cell Cancer Vaccines Products, Services and Solutions
    Table 114. Revenue (US$ Million) in Dendritic Cell Cancer Vaccines Business of Glaxo Smith Kline (2019-2024)
    Table 115. Glaxo Smith Kline Recent Developments
    Table 116. Tellaorporation Basic Information List
    Table 117. Tellaorporation Description and Business Overview
    Table 118. Tellaorporation Dendritic Cell Cancer Vaccines Products, Services and Solutions
    Table 119. Revenue (US$ Million) in Dendritic Cell Cancer Vaccines Business of Tellaorporation (2019-2024)
    Table 120. Tellaorporation Recent Developments
    Table 121. Vaxil BioTherapeutics Basic Information List
    Table 122. Vaxil BioTherapeutics Description and Business Overview
    Table 123. Vaxil BioTherapeutics Dendritic Cell Cancer Vaccines Products, Services and Solutions
    Table 124. Revenue (US$ Million) in Dendritic Cell Cancer Vaccines Business of Vaxil BioTherapeutics (2019-2024)
    Table 125. Vaxil BioTherapeutics Recent Developments
    Table 126. Key Raw Materials Lists
    Table 127. Raw Materials Key Suppliers Lists
    Table 128. Dendritic Cell Cancer Vaccines Downstream Customers
    Table 129. Dendritic Cell Cancer Vaccines Distributors List
    Table 130. Research Programs/Design for This Report
    Table 131. Key Data Information from Secondary Sources
    Table 132. Key Data Information from Primary Sources
    Table 133. Business Unit and Senior & Team Lead Analysts
List of Figures
    Figure 1. Dendritic Cell Cancer Vaccines Product Picture
    Figure 2. Global Dendritic Cell Cancer Vaccines Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Dendritic Cell Cancer Vaccines Sales Value (2019-2030) & (US$ Million)
    Figure 4. Dendritic Cell Cancer Vaccines Report Years Considered
    Figure 5. Global Dendritic Cell Cancer Vaccines Players Revenue Ranking (2023) & (US$ Million)
    Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Dendritic Cell Cancer Vaccines Revenue in 2023
    Figure 7. Dendritic Cell Cancer Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 8. CreaVax Picture
    Figure 9. Sipuleucel-T (Provenge) Picture
    Figure 10. Others Picture
    Figure 11. Global Dendritic Cell Cancer Vaccines Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 12. Global Dendritic Cell Cancer Vaccines Sales Value Market Share by Type, 2023 & 2030
    Figure 13. Product Picture of Pediatrics
    Figure 14. Product Picture of Adults
    Figure 15. Global Dendritic Cell Cancer Vaccines Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 16. Global Dendritic Cell Cancer Vaccines Sales Value Market Share by Application, 2023 & 2030
    Figure 17. North America Dendritic Cell Cancer Vaccines Sales Value (2019-2030) & (US$ Million)
    Figure 18. North America Dendritic Cell Cancer Vaccines Sales Value by Country (%), 2023 VS 2030
    Figure 19. Europe Dendritic Cell Cancer Vaccines Sales Value (2019-2030) & (US$ Million)
    Figure 20. Europe Dendritic Cell Cancer Vaccines Sales Value by Country (%), 2023 VS 2030
    Figure 21. Asia Pacific Dendritic Cell Cancer Vaccines Sales Value (2019-2030) & (US$ Million)
    Figure 22. Asia Pacific Dendritic Cell Cancer Vaccines Sales Value by Country (%), 2023 VS 2030
    Figure 23. South America Dendritic Cell Cancer Vaccines Sales Value (2019-2030) & (US$ Million)
    Figure 24. South America Dendritic Cell Cancer Vaccines Sales Value by Country (%), 2023 VS 2030
    Figure 25. Middle East & Africa Dendritic Cell Cancer Vaccines Sales Value (2019-2030) & (US$ Million)
    Figure 26. Middle East & Africa Dendritic Cell Cancer Vaccines Sales Value by Country (%), 2023 VS 2030
    Figure 27. Key Countries/Regions Dendritic Cell Cancer Vaccines Sales Value (%), (2019-2030)
    Figure 28. United States Dendritic Cell Cancer Vaccines Sales Value, (2019-2030) & (US$ Million)
    Figure 29. United States Dendritic Cell Cancer Vaccines Sales Value by Type (%), 2023 VS 2030
    Figure 30. United States Dendritic Cell Cancer Vaccines Sales Value by Application (%), 2023 VS 2030
    Figure 31. Europe Dendritic Cell Cancer Vaccines Sales Value, (2019-2030) & (US$ Million)
    Figure 32. Europe Dendritic Cell Cancer Vaccines Sales Value by Type (%), 2023 VS 2030
    Figure 33. Europe Dendritic Cell Cancer Vaccines Sales Value by Application (%), 2023 VS 2030
    Figure 34. China Dendritic Cell Cancer Vaccines Sales Value, (2019-2030) & (US$ Million)
    Figure 35. China Dendritic Cell Cancer Vaccines Sales Value by Type (%), 2023 VS 2030
    Figure 36. China Dendritic Cell Cancer Vaccines Sales Value by Application (%), 2023 VS 2030
    Figure 37. Japan Dendritic Cell Cancer Vaccines Sales Value, (2019-2030) & (US$ Million)
    Figure 38. Japan Dendritic Cell Cancer Vaccines Sales Value by Type (%), 2023 VS 2030
    Figure 39. Japan Dendritic Cell Cancer Vaccines Sales Value by Application (%), 2023 VS 2030
    Figure 40. South Korea Dendritic Cell Cancer Vaccines Sales Value, (2019-2030) & (US$ Million)
    Figure 41. South Korea Dendritic Cell Cancer Vaccines Sales Value by Type (%), 2023 VS 2030
    Figure 42. South Korea Dendritic Cell Cancer Vaccines Sales Value by Application (%), 2023 VS 2030
    Figure 43. Southeast Asia Dendritic Cell Cancer Vaccines Sales Value, (2019-2030) & (US$ Million)
    Figure 44. Southeast Asia Dendritic Cell Cancer Vaccines Sales Value by Type (%), 2023 VS 2030
    Figure 45. Southeast Asia Dendritic Cell Cancer Vaccines Sales Value by Application (%), 2023 VS 2030
    Figure 46. India Dendritic Cell Cancer Vaccines Sales Value, (2019-2030) & (US$ Million)
    Figure 47. India Dendritic Cell Cancer Vaccines Sales Value by Type (%), 2023 VS 2030
    Figure 48. India Dendritic Cell Cancer Vaccines Sales Value by Application (%), 2023 VS 2030
    Figure 49. Dendritic Cell Cancer Vaccines Industrial Chain
    Figure 50. Dendritic Cell Cancer Vaccines Manufacturing Cost Structure
    Figure 51. Channels of Distribution (Direct Sales, and Distribution)
    Figure 52. Bottom-up and Top-down Approaches for This Report
    Figure 53. Data Triangulation

Description

Dendritic cells (DCs) refer to rare kind of leukocytes. They have prompted their recent application to therapeutic cancer vaccinations as they are uniquely effective in their ability to present antigens to T cells. Isolated DCs loaded with tumor antigen ex vivo and administered as a cellular vaccine are found to induce protective and therapeutic anti-tumor immunity in experimental animals.

The global market for Dendritic Cell Cancer Vaccines was estimated to be worth US$ 601.3 million in 2023 and is forecast to a readjusted size of US$ 1436.3 million by 2030 with a CAGR of 13.1% during the forecast period 2024-2030

Market Segmentation